S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:VIR

Vir Biotechnology News Headlines

$34.00
-1.74 (-4.87%)
(As of 01/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$33.72
$36.25
50-Day Range
$30.97
$54.03
52-Week Range
$29.50
$141.01
Volume
1.28 million shs
Average Volume
1.73 million shs
Market Capitalization
$4.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.54
Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Vir Biotechnology Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VIR
News Sentiment

0.33

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VIR Articles
This Week

14

5

VIR Articles
Average Week



Vir Biotechnology (NASDAQ:VIR) News Headlines Today

SourceHeadline
finance.yahoo.com logobluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
finance.yahoo.com - January 19 at 2:14 PM
MarketBeat logoVir Biotechnology (NASDAQ:VIR) Stock Price Down 4%
americanbankingnews.com - January 19 at 12:54 PM
msn.com logoVir to extend COVID-19 treatment approach to HIV, malaria with $50M from Gates Foundation
msn.com - January 14 at 3:50 PM
finance.yahoo.com logoGlaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US
finance.yahoo.com - January 14 at 3:50 PM
seekingalpha.com logoEli Lilly and GlaxoSmithKline/Vir COVID-19 therapies get WHO backing
seekingalpha.com - January 14 at 6:58 AM
MarketBeat logoVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $48,262.50 in Stock
americanbankingnews.com - January 13 at 6:50 PM
seekingalpha.com logoVir Biotechnology, Gates Foundation expand partnership for treating HIV, malaria
seekingalpha.com - January 13 at 1:02 PM
seekingalpha.com logoGlaxoSmithKline, Vir seek FDA nod for intramuscular use of COVID-19 therapy
seekingalpha.com - January 13 at 11:49 AM
finance.yahoo.com logoVir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
finance.yahoo.com - January 13 at 11:49 AM
finance.yahoo.com logoVir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside Left in the Stock?
finance.yahoo.com - January 13 at 6:29 AM
seekingalpha.com logoVir extends gains as Needham lifts sales outlook for COVID-19 antibody therapy
seekingalpha.com - January 12 at 3:27 PM
MarketBeat logoVir Biotechnology (NASDAQ:VIR) Shares Up 5.4%
americanbankingnews.com - January 12 at 2:21 PM
finance.yahoo.com logoVir Biotechnology, Inc. (VIR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
finance.yahoo.com - January 12 at 11:56 AM
msn.com logoUS To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy
msn.com - January 11 at 2:46 PM
msn.com logoGSK, Vir to supply US government with 600,000 doses of Covid-19 drug
msn.com - January 11 at 1:50 PM
msn.com logoGlaxoSmithKline, Vir Say U.S. to Buy 600,000 More Covid Doses
msn.com - January 11 at 1:50 PM
MarketBeat logoVir Biotechnology (NASDAQ:VIR) Shares Gap Up to $33.42
americanbankingnews.com - January 11 at 10:50 AM
msn.com logoU.S. secures 600,000 more doses of GSK-Vir's COVID-19 therapy
msn.com - January 11 at 9:45 AM
markets.businessinsider.com logoGSK, Vir To Supply Additional 60k Doses Of Sotrovimab To US Govt. For Early Treatment Of Covid-19
markets.businessinsider.com - January 11 at 9:45 AM
seekingalpha.com logoVir Biotechnology jumps 8% on purchase agreement of Sotrovimab with the US government
seekingalpha.com - January 11 at 9:45 AM
seekingalpha.com logoGSK, Vir to provide U.S. with 600K additional doses of COVID treatment sotrovimab
seekingalpha.com - January 11 at 9:45 AM
msn.com logoTesla, Vir Biotechnology, Illumina Rise Premarket; Rivian Falls
msn.com - January 11 at 8:50 AM
markets.businessinsider.com logoGSK Signs Addl Purchase Agreements With Canada For COVID-19 Monoclonal Antibody Therapy, Sotrovimab
markets.businessinsider.com - January 6 at 11:34 PM
finance.yahoo.com logoNotable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer
finance.yahoo.com - January 6 at 6:33 PM
finance.yahoo.com logoGlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses
finance.yahoo.com - January 6 at 6:33 PM
finance.yahoo.com logoVir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:32 PM
benzinga.com logoVir Biotechnology Announces New Research Describing Structural Basis Of SARS-CoV-2 Omicron Immune Evasion And Receptor Engagement
benzinga.com - December 31 at 11:16 AM
benzinga.com logoUPDATE: Vir Biotechnology Says Sotrovimab Continues To Maintain Activity Against All Tested Variants Of Concern And Interest, Including Omicron
benzinga.com - December 31 at 11:16 AM
finance.yahoo.com logoImplied Volatility Surging for Vir Biotechnology (VIR) Stock Options
finance.yahoo.com - December 31 at 11:16 AM
insidertrades.com logoInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 1,375 Shares of Stock
insidertrades.com - December 30 at 6:14 PM
finance.yahoo.com logoGILD or VIR: Which Is the Better Value Stock Right Now?
finance.yahoo.com - December 29 at 3:14 PM
benzinga.com logoVir Biotechnology shares are trading lower after Baird downgraded the stock from Neutral to Underperform.
benzinga.com - December 23 at 5:38 AM
msn.com logoBiotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
msn.com - December 22 at 12:39 PM
finance.yahoo.com logoTime To Worry? Analysts Just Downgraded Their Vir Biotechnology, Inc. (NASDAQ:VIR) Outlook
finance.yahoo.com - December 22 at 7:38 AM
benzinga.com logoWhere Vir Biotechnology Stands With Analysts
benzinga.com - December 21 at 3:03 PM
benzinga.com logoThinking about trading options or stock in Moderna, Vir Biotechnology, BioNTech, Cerner Corp, or Apple?
benzinga.com - December 20 at 1:16 PM
finance.yahoo.com logoVir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
finance.yahoo.com - December 20 at 1:16 PM
nasdaq.com logoVir And GSK's Sotrovimab Gets EC Marketing Authorization For Early Treatment Of Covid-19
nasdaq.com - December 17 at 12:34 PM
msn.com logoGlaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19
msn.com - December 17 at 12:34 PM
finance.yahoo.com logoXevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
finance.yahoo.com - December 17 at 8:31 AM
benzinga.com logoVir Biotechnology's Stock Rally Seems To Have More Runway Left
benzinga.com - December 16 at 5:12 PM
barrons.com logoPremarket Movers: Confluent, Accenture Cl A, Vir Biotechnology
barrons.com - December 16 at 7:48 AM
finance.yahoo.com logoWhy Are Vir Biotech Shares Gaining Today?
finance.yahoo.com - December 15 at 3:54 PM
finance.yahoo.com logoVir Biotechnology Surges on Evidence Therapy Useful Against Omicron
finance.yahoo.com - December 15 at 3:54 PM
finance.yahoo.com logoPublicly traded biotech firm expands to St. Louis with new Cortex office
finance.yahoo.com - December 15 at 3:54 PM
barrons.com logoVir and Glaxo’s Drug Could Be the Last Antibody Treatment Standing Against Omicron
barrons.com - December 15 at 10:34 AM
benzinga.com logoThinking about trading options or stock in Vir Biotechnology, Pfizer, Apple, Tesla, or AMC Entertainment?
benzinga.com - December 14 at 11:24 PM
finance.yahoo.com logoPreclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
finance.yahoo.com - December 14 at 6:23 PM
barrons.com logoPremarket Movers: Vir Biotechnology, Bank of Montreal, AMC Entertainment Hldgs
barrons.com - December 14 at 8:22 AM
finance.yahoo.com logoVir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
finance.yahoo.com - December 9 at 8:45 AM
Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.